Background: Psychotherapy has proven to be an effective treatment modality
in children and adolescents with depressive illness. The American Academy o
f Child and Adolescent Psychiatry advocates the use of selective serotonin
reuptake inhibitors (SSRIs) as first-line pharmacotherapy in the treatment
of depression without comorbid mental illness. Tricyclic antidepressants (T
CAs) are not recommended as first-line treatment because of insufficient ev
idence of their efficacy in children and adolescents, as well as potential
adverse effects.
Objective: The present study was designed to determine the extent of the us
e of antidepressant pharmacotherapy and/or psychotherapy among children and
adolescents in the United States aged 5 through 18 years with a diagnosis
of depressive illness.
Methods: Using data from the National Ambulatory Medical Care Survey (NAMCS
) for 1990 through 1995, office-based physician-patient encounters (ie, off
ice visits) documenting the use of antidepressant pharmacotherapy and/or a
recorded diagnosis of depression were obtained. The rate per 1000 office vi
sits for children and adolescents aged 5 through 18 years and the rate per
1000 US population aged 5 through 18 years were calculated for: (1) prescri
bing of antidepressant pharmacotherapy for any reason; (2) recorded diagnos
is of depression with or without comorbid mental illness; (3) diagnosis of
depression with or without comorbid mental illness resulting in the prescri
bing of antidepressant pharmacotherapy; (4) diagnosis of depression without
comorbid mental illness; and (5) diagnosis of depression without comorbid
mental illness resulting in the prescribing of antidepressant pharmacothera
py. Treatment modalities used in the management of depressive illness (phar
macotherapy, psychotherapy, both, or neither) are reported as percentages o
f the total number of office visits for the 1990-1992 period and for 1995 (
the years for which data on the use of psychotherapy were recorded in the N
AMCS).
Results: Between 1990 and 1995, an estimated 4,638,608 office visits docume
nted the prescribing of antidepressant pharmacotherapy for any reason in ch
ildren and adolescents aged 5 through 18 years (9.0 per 1000 encounters; 15
.3 per 1000 population). The majority of encounters (58.2%) documented the
prescribing of a TCA. The rate of a documented diagnosis of depression with
or without comorbid mental illness was 8.0 per 1000 encounters and 13.6 pe
r 1000 population. The rate for a documented diagnosis of depression with o
r without comorbid mental illness, in concert with the prescribing of antid
epressant pharmacotherapy, was 3.9 per 1000 encounters and 6.6 per 1000 pop
ulation. The rate for a documented diagnosis of depression without comorbid
mental illness was 5.1 per 1000 encounters and 8.7 per 1000 population. Th
e rate for a documented diagnosis of depression without comorbid mental ill
ness, in concert with the prescribing of antidepressant pharmacotherapy, wa
s 2.6 per 1000 encounters and 4.4 per 1000 population. Of the 1,327,466 pat
ients with a recorded diagnosis of depression without comorbid mental illne
ss who were prescribed antidepressant pharmacotherapy, 54.9% received an SS
RI, and 39.8% a TCA. During the 1990-1992 period and in 1995, the modality
of treatment for patients with a documented diagnosis of depression without
comorbid mental illness was antidepressant pharmacotherapy alone in 12.7%
of patients, psychotherapy alone in 31.8%, psychotherapy and antidepressant
pharmacotherapy in 36.0%, and neither psychotherapy nor antidepressant pha
rmacotherapy in 19.5%.
Conclusions: The use of psychotherapy and antidepressant pharmacotherapy fo
r the treatment of depressive illness in US children and adolescents is ext
ensive. The use of the TCAs in patients with a documented diagnosis of depr
ession without comorbid mental illness is widespread even though this drug
class is not recommended as first-line therapy in this population. Approxim
ately 19% of children and adolescents with a recorded diagnosis of depressi
ve illness received neither psychotherapy nor pharmacotherapy. This finding
may reflect problems associated with access to health insurance, the cover
age of mental health services under insurance policies, geographic distribu
tion of mental health services, and/or decisions by patients or guardians.